Epha3 and multi-valent targeting of tumors
AssigneeWake Forest University Health Sciences
InventorsWaldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
Life of this patent
Estimating the term…
Abstract
Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
Claims20
A construct comprising, in combination:
- a ligand that binds to EphA2, EphA3, and EphB2;
- and
- at least one effector molecule.
A polypeptide comprising a mutant eA5, or an EphA2, EphA3 and/or EphB2 binding fragment thereof, or a nucleic acid encoding a polypeptide comprising a mutant eA5, or an EphA2, EphA3 and/or EphB2 binding fragment thereof.
Dependencies are inferred from the claim text.